Sensus Healthcare Business Summary

Sensus Healthcare, Inc. (SRTS) is a medical device manufacturer specializing in non-invasive superficial radiotherapy (SRT) for the treatment of non-melanoma skin cancer and keloids. The company generates revenue through three primary channels: direct capital equipment sales of its SRT-100, SRT-100+, and SRT-100 Vision systems; its "Fair Deal Agreement" (FDA) model, a revenue-sharing shared-service program; and recurring streams from its Sentinel service contracts and safety disposables. As of early 2026, Sensus has undergone a pivotal business model shift following the implementation of exclusive CMS Current Procedural Terminology (CPT) codes, which provide a 300% per-fraction reimbursement increase for SRT delivery. This regulatory milestone has allowed the company to diversify its customer base away from historical concentration and target full-year profitability. Within the medical equipment landscape, Sensus maintains a specialized niche in dermatological oncology, competing against broader medical technology firms such as Sight Sciences (SGHT), Profound Medical (PROF), and Semler Scientific (SMLR) by positioning its SRT technology as a cost-effective, non-surgical alternative to Mohs surgery. Sensus was founded in 2010 by Joseph C. Sardano, Richard Golin, Kalman Fishman, and Stephen Cohen. The leadership team is headed by Co-Founder, Chairman, and CEO Joseph C. Sardano, a 30-year industry veteran with prior executive roles at GE Medical Systems, Siemens, and CTI Molecular Imaging. The executive suite includes Michael J. Sardano (President, Chief Commercial Officer, and General Counsel), Javier Rampolla (CFO), Magdalena Martinez (COO), and Emiliano Sosa (CTO). The company’s Board of Directors has been recently strengthened by the appointments of Eric Sachetta in late 2025 and Larry Biscotti in January 2026; Biscotti currently serves as the President of Imaging for the U.S. and Canada at GE HealthCare. Institutional backing includes significant positions from The Vanguard Group, Pacific Ridge Capital Partners, and Dimensional Fund Advisors, reflecting a stable ownership structure as the company executes its 2026 global expansion strategy.